

Russian Federation

Tuberculosis profile

Population 2016

144 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	12 (11–12)	8.2 (7.8–8.6)
Mortality (HIV+TB only)	1.7 (0.85–2.7)	1.2 (0.59–1.9)
Incidence (includes HIV+TB)	94 (61–135)	66 (42–94)
Incidence (HIV+TB only)	18 (12–26)	13 (8.1–18)
Incidence (MDR/RR-TB)**	63 (52–74)	44 (36–51)

Estimated TB incidence by age and sex (thousands)*, 2016

	0-14 years	> 14 years	Total
Females	4.7 (2.9–6.6)	25 (15–35)	30 (18–42)
Males	5.4 (3.3–7.5)	59 (36–82)	65 (39–90)
Total	10 (6.1–14)	84 (51–118)	94 (61–135)

TB case notifications, 2016

Total cases notified	121 046
Total new and relapse	92 407
- % tested with rapid diagnostics at time of diagnosis	70%
- % with known HIV status	87%
- % pulmonary	91%
- % bacteriologically confirmed among pulmonary	51%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	98% (68–150)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.15 (0.1–0.21)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	16 570	21%
- on antiretroviral therapy	10 549	64%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			47 000 (46 000–47 000)
Estimated % of TB cases with MDR/RR-TB	27% (27–28)	65% (65–66)	
% notified tested for rifampicin resistance	40%	63%	57 910
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: 27 363, XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: 25 713, XDR-TB: 1 772	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	71%	80 424
Previously treated cases, excluding relapse, registered in 2015	50%	8 294
HIV-positive TB cases registered in 2015	51%	694
MDR/RR-TB cases started on second-line treatment in 2014	51%	20 089
XDR-TB cases started on second-line treatment in 2014	31%	2 209

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	93%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017

National TB budget (US\$ millions)	1 175
Funding source: 100% domestic, 0% international, 0% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically